AQST News and Press, Aquestive Therapeutics Inc. From 08/02/22

Aquestive Therapeutics press release ( NASDAQ: AQST ): Q2 GAAP EPS of -$0.36 in-line. Revenue of $13.27M (-13.5% Y/Y) beats by $2.7M . 2022 Guidance: Total revenue (in millions) - $46 to $49M from prior forecast $42 to $47M($46.46M consensus) For fur...

Completed EPIPHAST trial successfully demonstrating rapid and significant epinephrine exposure under a variety of real-world conditions after administration of AQST-109 (epinephrine sublingual film) Initiated EPIPHAST II trial, comparing AQST-109 to epinephrine 0.3mg IM injection (r...

WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the managemen...

WARREN, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it wil...

Study results for the sublingual administration of AQST-109 epinephrine oral film after consuming a peanut butter sandwich demonstrates consistent Tmax of 12 minutes Study results for swallowing AQST-109 whole immediately with water showed an unexpectedly high level of gastroint...

Aquestive Therapeutics (NASDAQ:AQST) added ~31% in the post-market Wednesday after the commercial-stage pharma company announced topline results from the first three arms of Part 3 of the randomized, open-label study for AQST-109 epinephrine oral film. The three-part crossover EPIPH...

AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development Fastest median time to maximum concentration (Tmax) in studies to date at 12 minutes Study continues to show AQST-109 is safe and well tolerated Head-to-head c...

WARREN, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has...

WARREN, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the managemen...

Aquestive Therapeutics (NASDAQ:AQST) +1.5% announced Monday a direct stock offering worth $8.5M, comprising of 8.85M shares priced at $0.96 each. It will also include the warrants to purchase up to an aggregate of 8.85M shares for 5-year term, exercisable at a purchase price of...